Skip to content
FDA Import Alert · 66-40

LCC Ltd. · Eumseong, KOREA (THE REPUBLIC OF)

Listed 2023-05-03 · 10 product codes · Source: FDA Import Alert 66-40 · View on FDA

A facility listed under this company name on the FDA Import Alert list as checked on 2026-11-09. See the FDA page for the listed address and products. Full Import Alert list

Firm Record

LCC Ltd.

14 findings from 2 inspection documents published by regulators. Each row below says what its date means.

US FDA · 2024-12-03 ~ 2026-10-20

Areas cited

Laboratory and QC controlsMaterial and supplier controlQuality unit oversightProcess validationTraining and personnelDocumentation and recordsComplaint and recall handlingEquipment and facilityStability and storage

Published inspection documents

Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)). You contract manufacture over-the-counter (OTC) drug products such as anticavity mouthwash. You failed to conduct an adequate identity test on each shipment of each lot of components used in the production of your drug products. Additionally, you relied on the certificates of analysis (COA) from your suppliers and failed to establish the reliability of each of your suppliers’ COA for component specifications and characteristics at appropriate intervals. Glycerin, Propylene Glycol, and (b)(4) You failed to adequately test each shipment of each lot of glycerin, propylene glycol, and (b)(4) for identity, components at higher risk for diethylene glycol (DEG) and ethylene glycol (EG) contamination. We note that glycerin, propylene glycol, and (b)(4) are ingredients used in your OTC mouthwash drug products. Identity testing for glycerin and certain other high-risk drug components include a DEG/EG limit test in the United States Pharmacopeia (USP) to ensure that the component meets the relevant safety limits. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to ensure the acceptability of these components for use in the manufacture of your drug products. In your response, you state that you will “take action” to have your customers “ship back” to your firm all OTC drug products exported to the United States (U.S.) market. You also indicated that you notified your customer, label owner (b)(4) , to hold its remaining inventory and “explained the required recall procedure.” Furthermore, you provided documents showing that you performed identity testing on your current raw material lots of glycerin, propylene glycol, and (b)(4) for DEG and EG contamination. Your response is inadequate. Identity testing performed on your current raw materials lots for DEG and EG contamination, failed to address potential impact on all drug product lots distributed to the United States that remain within expiry that were manufactured with untested components. The use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https://www.fda.gov/media/167974/download. In response to this letter, provide a full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination (including, but not limited to, glycerin). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate corrective action and preventive action (CAPA) that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter. 2024-12-03 US FDA 3 findingsMaterial and supplier control · Laboratory and QC controls and 1 more View the regulator's official source

21 CFR sections cited in FDA inspections

Citations from 1 FDA inspection (2024-03-22) of facilities listed under this company name in FDA's inspection citation data.

As written by FDAInspectionLatest inspection
21 CFR 211.110(a)Control procedures to monitor and validate performance12024-03-22
21 CFR 211.137(a)Expiration date lacking12024-03-22
21 CFR 211.160(b)Scientifically sound laboratory controls12024-03-22
21 CFR 211.180(c)Records not made readily available to FDA12024-03-22
21 CFR 211.188Prepared for each batch, include complete information12024-03-22
21 CFR 211.198(b)(2)Complaint Investigation/Follow-Up Findings12024-03-22
21 CFR 211.22(c)Approve or reject procedures or specs12024-03-22
21 CFR 211.25(b)Supervisor Training/Education/Experience12024-03-22
21 CFR 211.63Equipment Design, Size and Location12024-03-22
21 CFR 211.67(b)(3)Cleaning SOPs/instructions12024-03-22
21 CFR 211.84(d)(2)Reports of Analysis (Components)12024-03-22

1 site: LCC Ltd. (Eumseong, Korea (the Republic of)) · 1 inspection

Source: FDA Data Dashboard - Inspections Citations, as of 2026-11-08. Only inspections with at least one citation are included, and a section cited more than once in one inspection counts once. Only facilities whose name and legal form match this page's documents, and that are listed in a single country, are included.

Other companies with similar findings

Other companies with findings worded closely to this company's. Only documents of the same type are compared.

A record as of publication. Check the agency's own announcements for any later corrective action.

What is included. As collected on 2026-11-15: only documents with a detail page (3 or more findings). See the firm lookup for everything.

Full history of LCC Ltd. — including inspection classifications Browse by document Go to Findings search
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.